PITTSBURGH, May 28 /PRNewswire/ -- Falcon Genomics, Inc. announced today that it has received U.S. Patent # 7,537,913 with claims covering the Company’s Cancer BioChip System (CBCS) for the identification and validation of potential cancer targets in a high-throughput in vitro setting with great clinical translational potential.
The patent claims are supported by experimental validation with human breast cancer cells using Falcon Genomics’ first-generation Cancer BioChip System (CBC-1). These results, recently presented at the 6th Annual Conference on Cancer Drugs Research and Development in Philadelphia, PA (February 19, 2009) represent the first reported use of high-throughput one-step delivery of silencing RNA (siRNA) into cells growing in an anchorage-independent manner with real-time evaluation of cell growth.
“Cancer is analogous to a physiological train-wreck. It only takes a small number of defective signals to trigger the multitudes of abnormal molecular profiles observed within cancer cells. Triggering molecules are the ones that must be targeted for therapy,” said Dr. Rula Abbud-Antaki, President and Chief Scientific Officer of Falcon Genomics. “Our proprietary technology will provide personalized identification of cancer- initiating events, and formulation of efficient and accurate therapies.”
According to Dr. Peter D. Mlynek, a patent attorney with the law firm of Eckert Seamans, the Cancer BioChip System is a unique and highly useful technology. “The U.S. Patent Office has found the claimed CBCS to be novel and non-obvious.”
About Falcon Genomics, Inc.
Falcon Genomics, Inc. is a private Pittsburgh-based biotech company founded in August 2004. The goal of the company is to provide cutting edge technologies, including functional genomics, for the accurate diagnosis of cancer patients and the personalized formulation of therapeutic strategies. Falcon Genomics currently provides CBCS services for research and pharmaceutical institutions working at the forefront of cancer diagnostics and therapeutics.
For more information, please visit: www.falcongenomics.com
